WealthPLAN Partners LLC Sells 2,582 Shares of Pfizer Inc. (NYSE:PFE)

WealthPLAN Partners LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 25.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,584 shares of the biopharmaceutical company’s stock after selling 2,582 shares during the quarter. WealthPLAN Partners LLC’s holdings in Pfizer were worth $212,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Wulff Hansen & CO. raised its stake in shares of Pfizer by 2,698.0% during the 2nd quarter. Wulff Hansen & CO. now owns 269,000 shares of the biopharmaceutical company’s stock worth $7,527,000 after purchasing an additional 259,386 shares during the period. Renaissance Technologies LLC raised its position in Pfizer by 18.6% in the second quarter. Renaissance Technologies LLC now owns 4,700,173 shares of the biopharmaceutical company’s stock worth $131,511,000 after acquiring an additional 735,536 shares during the period. Citizens Financial Group Inc. RI raised its position in Pfizer by 63.5% in the second quarter. Citizens Financial Group Inc. RI now owns 200,310 shares of the biopharmaceutical company’s stock worth $5,605,000 after acquiring an additional 77,780 shares during the period. One Capital Management LLC boosted its stake in Pfizer by 32.0% in the second quarter. One Capital Management LLC now owns 270,681 shares of the biopharmaceutical company’s stock valued at $7,574,000 after acquiring an additional 65,631 shares during the last quarter. Finally, Sierra Summit Advisors LLC grew its position in shares of Pfizer by 4.9% during the 2nd quarter. Sierra Summit Advisors LLC now owns 349,690 shares of the biopharmaceutical company’s stock valued at $9,784,000 after acquiring an additional 16,472 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on PFE shares. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays upped their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. UBS Group boosted their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Trading Down 0.8 %

Pfizer stock opened at $29.83 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.12. The stock has a market cap of $169.04 billion, a P/E ratio of -497.08, a PEG ratio of 1.02 and a beta of 0.68. The firm’s fifty day moving average price is $29.30 and its 200-day moving average price is $28.18.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were given a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.63%. Pfizer’s payout ratio is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.